Leiden University Medical Center (LUMC)
Leiden, 2333ZA, Netherlands
NCT Number: NCT06421532
A pre-post study will be conducted to assess whether treatment with LXB, nVNS or a combination of both interventions can enhance the clearance of Aβ in patients with CAA. A total of 60 subjects, 30 with sCAA and 30 with D-CAA, will be randomly assigned to receive LXB, or both interventions. The primary outcome measure will be the morning levels of Aβ40 and Aβ42 in cerebrospinal fluid (CSF) before and after the intervention. The investigators will assess disease progression with (non-)haemorrhagic imaging markers on 7-Tesla Magnetic Resonance Imaging (7-T MRI) as a secondary outcome. Additionally, the activity of the glymphatic system by means of fluid dynamics will be assessed using 7-T MRI.
Interested in participating?
Request Info30 year and older
All sexes
Interventional
Phase 2
Leiden, 2333ZA, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Contraindications for using LXB:
Contraindications for lumbar puncture:
Contraindications for nVNS:
Contraindications for 7 Tesla MRI as determined by the 7 Tesla safety committee. Examples of possible contra-indications are:
Specific contraindications for checkerboard functional Magnetic Resonance Imaging (fMRI):
Daily before bedtime for 3 months
Twice daily for 3 months
Time frame: 3 months
Difference between before and after intervention
Time frame: 2x 3 months
Macrobleeds
Time frame: 2x 3 months
Cerebral microbleeds
Time frame: 2x 3 months
Cortical superficial siderosis
Time frame: 2x 3 months
Convexity subarachnoid haemorrhage
Time frame: 2x 3 months
Periventricular and deep white matter hyperintensity volume
Time frame: 2x 3 months
Cerebrovascular reactivity
Time frame: 2x 3 months
Interaction between CSF-mobility at the 4th ventricle and brain vasomotion
Time frame: 2x 3 months
Total CAA-related cerebral small vessel disease (CAA-CSVD) score
Time frame: 2x 3 months
CSF-mobility (in mm2/s)
Time frame: 2x 3 months
Principal orientation of CSF-mobility
Time frame: 2x 3 months
Fractional anisotropy
Time frame: 3 months
Difference in Aβ-levels 40 and 42 in CSF comparing the three intervention groups and the BATMAN placebo control group.
Time frame: 3 months
Levels of amyloid-beta 38, 43, t-tau and p-tau181 in CSF
Time frame: 3 months
Levels of amyloid-beta 40 and 42 in serum
Time frame: 2x 3 months
Cognitive status using the Montreal Cognitive Assessment (MoCA)
Time frame: 2x 3 months
Symptoms of depression and anxiety using the Hospital Anxiety and Depression Scale (HADS)
Time frame: 2x 3 months
Quality of life using the 36-item Short Form healthy survey (SF-36)
Time frame: 2x 3 months
Quality of sleep using the Pittsburgh Sleep Quality Index (PSQI)
Time frame: 2x 3 months
Severity of insomnia using the Insomnia Severity Index (ISI)
Time frame: 3 months
Compliance, side effects and tolerability of nVNS and LXB
Time frame: 3 months
The number of participants developing sleep apnoea during intervention
Leiden University Medical Center
Other
A Partial Randomised Clinical Trial Investigating Stimulation of the Glymphatic System by Either Deepening Sleep With Lower-sodium Oxybate or Inhibiting Cortical Spreading Depressions With Non-invasive Vagus Nerve Stimulation, or Both, in Patients With Cerebral Amyloid Angiopathy (CAA)
Acronym: Clear-Brain
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06393712
Amyloidosis, Brain Diseases
Los Angeles, California, United States
View Trial DetailsNCT07250035
Amyloidosis, Brain Diseases
Beijing, China
View Trial DetailsNCT06888882
Amyloidosis, Brain Diseases
Nîmes, Occitanie, France
View Trial DetailsNCT04204642
Amyloidosis, Brain Diseases
Milan, Milano, Italy
View Trial Details